News EU approves CSL's once-monthly HAE drug Andembry The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst.
News CSL preps filings for once-monthly antibody for HAE Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial y
News New UK PM shuts down science and tech department In the midst of appointing his Cabinet, new UK Prime Minister Andy Burnham has scrapped the Department for Science, Innovation and Technology (DSIT).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
